Diego Pedroza Lab

About the Lab

Our lab studies how the spatial landscape of the tumor immune microenvironment (TIME) governs therapy response in metastatic triple negative breast cancer (TNBC). Lung and liver metastases harbor distinct, organ-specific immune niches that display intratumoral heterogeneity (ITH) that can lead to therapeutic resistance. We seek to define spatial tumor immune programs that predict response versus resistance to immunotherapy, chemotherapy, and combination regimens and to determine whether targeting these programs can overcome resistance in patients with metastatic TNBC. Our pre-clinical studies have already translated into an active clinical trial (NCT06959537), and through spatial profiling of patient tumor tissue alongside longitudinal blood-based immune monitoring, we aim to study biomarkers that predict response and guide therapy selection for patients with metastatic TNBC.

Publications

Pedroza DA, Yuan X, Liu F, Chan HL, Zhang C, Bowie W, Smith AJ, Calderon SJ, Lieu N, Wu W, Porter P, Sarkar P, Zhao N, Oehler CV, Peller O, Gaber MW, Zhu Q, Perou CM, Zhang XH, Rosen JM. Anti-CSF-1R therapy with combined immunochemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers. Nat Commun. 2026 Jan 3;17(1):1193. PubMed Central PMCID: PMC12858953 .

Pedroza DA, Gao Y, Zhang XH, Rosen JM. Leveraging preclinical models of metastatic breast cancer. Biochim Biophys Acta Rev Cancer. 2024 Sep;1879(5):189163. PubMed Central PMCID: PMC11390310 .

Singh S, Lee N, Pedroza DA, Bado IL, Hamor C, Zhang L, Aguirre S, Hu J, Shen Y, Xu Y, Gao Y, Zhao N, Chen SH, Wan YW, Liu Z, Chang JT, Hollern D, Perou CM, Zhang XHF, Rosen JM. Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast Cancer. Cancer Res. 2022 Jun 15;82(12):2281-2297. PubMed Central PMCID: PMC9219596.

Currently Recruiting

We are currently looking to recruit a Postdoc Associate and Research Tech III. Please email if interested.